BioNTech, a German pharmaceutical company, and Pfizer, a US-based pharmaceutical business, warned on Saturday that they are unsure if their coronavirus vaccinations can help treat the new COVID-19 strain ‘Omicron.’
In “roughly 100 days,” the pharmaceutical companies said they will produce a new vaccine against the covid strain discovered in South Africa.
This arose when the World Health Organization (WHO) identified a new COVID-19 strain, the B.1.1.529, first discovered in South Africa, as a highly transmissible virus of concern and gave it the Greek letter “omicron” to represent it.
“If a vaccine-escape variant emerges, Pfizer and BioNTech hope to be able to create and deliver a custom vaccine against that variant in around 100 days, subject to regulatory approval,” the companies said in a statement.
Pfizer and BioNTech said in a statement that more data on Omicron will be available in the next two weeks, adding that the version differs dramatically from prior ones, according to Sputnik.
According to the announcement, the businesses began working on making their coronavirus vaccine adaptable in six weeks and shipping initial batches in 100 days.
